Reyataz
NDC Package 69189-3624-1
Package Information
Reyataz is ® (atazanavir) is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection for patients 3 months and older weighing at least 5 kg.Limitations of Use:•REYATAZ is not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus.•Use of REYATAZ/ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [see Microbiology (12.4)]. Marketed by Avera Mckennan Hospital, this product is identified by NDC 69189-3624 and is authorized under FDA application NDA021567.
Identification & Billing
- RxCUI: 402094 - Reyataz 150 MG Oral Capsule
- RxCUI: 402094 - atazanavir 150 MG Oral Capsule [Reyataz]
- RxCUI: 402246 - atazanavir sulfate 150 MG Oral Capsule
- RxCUI: 402246 - atazanavir 150 MG Oral Capsule
- RxCUI: 402246 - atazanavir 150 MG (as atazanavir sulfate 170.8 MG) Oral Capsule
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 69189 - Avera Mckennan Hospital
- 69189-3624 - Reyataz
- 69189-3624-1 - 1 CAPSULE, GELATIN COATED in 1 DOSE PACK
- 69189-3624 - Reyataz
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 69189-3624-1 identifies a specific commercial package of 1 capsule, gelatin coated in 1 dose pack of Reyataz, labeled by Avera Mckennan Hospital. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Avera Mckennan Hospital on April 28, 2015. The current certification is valid through December 31, 2018.
How is this Avera Mckennan Hospital product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 69189362401. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.